James Lee analyst

Currently out of the existing stock ratings of James Lee, 323 are a BUY (64.34%), 16 are a SELL (3.19%), 163 are a HOLD (32.47%).

James Lee

Work Performance Price Targets & Ratings Chart

Analyst James Lee, carries an average stock price target met ratio of 60.57% that have a potential upside of 36.63% achieved within 168 days. Previously, James Lee worked at MIZUHO, CLSA.

James Lee’s has documented 1,111 price targets and ratings displayed on 53 stocks. The coverage was on Communication Services, Consumer Cyclical, Healthcare, Technology, Financial Services sectors.

Most recent stock forecast was given on TCOM, Trip.com Group Ltd ADR at 25-Jun-2026.

Wall Street Analyst James Lee

Analyst best performing recommendations are on CORT (CORCEPT THERAPEUTICS).
The best stock recommendation documented was for CORT (CORCEPT THERAPEUTICS) at 8/2/2023. The price target of $29 was fulfilled within 1 day with a profit of $3.99 (15.95%) receiving and performance score of 159.54.

Average potential price target upside

ABNB Airbnb  AMZN Amazon.com ARGX argenx NV ADR AXSM Axsome Therapeutics BABA Alibaba Group Holding Ltd BIDU Baidu BKNG Booking Holdings CNCE Concert Pharmaceuticals CPNG Coupang LLC DASH DoorDash Common Stock EBAY eBay EXPE Expedia Group FB Meta Platforms GOOG Alphabet Class C GOOGL Alphabet JD JD.com Adr META Meta Platforms SAGE Sage Therapeutic TCOM Trip.com Group Ltd ADR TRIP TripAdvisor TRVG Trivago NV TWTR Twitter UBER Uber Technologies A Agilent Technologies ADVM Adverum Biotechnologies ANAB AnaptysBio CPRX Catalyst Pharmaceuticals NTLA Intellia Therapeutics GBT Global Blood Therapeutics RARE Ultragenyx MRNS Marinus Pharmaceuticals WVE Wave Life Sciences Ltd CRMD CorMedix EDIT Editas Medicine APTX Aptinyx ARVN Arvinas CRSP Crispr Therapeutics AG CTRP Trip.com Group EBC Eastern Bankshares LJPC La Jolla Pharmaceutical Co PRFT Perficient RLMD Relmada Therapeutics TCEHY Tencent Holdings Ltd ADR TSHA Taysha Gene Therapies  VKTX Viking Therapeutics VRNA Verona Pharma PLC ADR CORT Corcept Therapeutics BILI Bilibili DADA Dada Nexus Ltd GRUB GrubHub SABR Sabre Corpo TC TuanChe ADR TW Tradeweb Markets

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 13-Feb-2026

$125

$-7.85 (-5.91%)

$122

1 months 27 days ago
(11-May-2026)

2/7 (28.57%)

$-12.05 (-8.79%)

19

Buy Since 05-May-2025

$162

$29.15 (21.94%)

$150

1 months 27 days ago
(11-May-2026)

14/24 (58.33%)

$24.95 (18.21%)

89

Buy Since 20-Apr-2022

$175

$42.15 (31.73%)

$158

2 months ago
(08-May-2026)

14/18 (77.78%)

$33.51 (23.68%)

152

Buy Since 11-Apr-2024

$160

$27.15 (20.44%)

$145

2 months ago
(08-May-2026)

3/10 (30%)

$18.51 (13.08%)

154

Buy Since 08-May-2026

$173

$40.15 (30.22%)

$170

2 months ago
(08-May-2026)

13/16 (81.25%)

$31.51 (22.27%)

30

Show more analysts

Please expand the browser size to see the chart

Which stock is James Lee is most bullish on?

Potential upside of $252.1 has been obtained for META (META PLATFORMS)

Which stock is James Lee is most reserved on?

Potential downside of $6.44 has been obtained for CPNG (COUPANG LLC)

What Year was the first public recommendation made by James Lee?

On 2013

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?